Riverpoint Medical

Riverpoint Medical

Riverpoint Medical was founded in 2005 in Portland, Oregon by medical-device veterans Patrick Ferguson and James H. Coleman as a privately held manufacturer of surgical sutures, orthopedic implants, and medical textiles. The firm has no reported outside funding rounds, operating as an organically financed industrial company rather than a venture-backed device startup. Its founding thesis targeted the gap between commodity suture suppliers and J&J's Ethicon franchise — offering private-label and OEM manufacturing for hospitals, integrated delivery networks, and med-tech brands that wanted high-spec braided-and-coated suture lines without building their own cleanroom infrastructure. The firm's deployment spans four linked product categories: braided and monofilament surgical sutures including UHMWPE and polyester formulations, orthopedic fixation devices such as knotless suture anchors and interference screws, woven and knitted medical textiles for cardiovascular and hernia-repair meshes, and bioresorbable polymer implants for sports medicine. Riverpoint operates an FDA-registered, ISO 13485-certified design and prototyping center in Portland while running full cleanroom manufacturing at its 80,000-square-foot facility in Alajuela, Costa Rica, with additional assembly in Tijuana, Mexico. The firm participates in direct OEM and private-label contracts with Tier-1 med-tech distributors, hospital purchasing organizations, and boutique sports-medicine brands. Riverpoint has scaled quietly without disclosing headcount or revenue. Its Costa Rica manufacturing complex underwent a major expansion in 2022 that reportedly doubled cleanroom square footage (per the firm's regulatory filings and local Costa Rican trade press, 2022). That expansion, combined with a 2023 FDA 510(k) clearance for a new barbed-suture line for laparoscopic soft-tissue approximation, suggests the firm is deepening its commitment to the high-barrier bio-design space where J&J and Medtronic/Covidien hold concentrated market share. What distinguishes Riverpoint structurally is its hybrid architecture: it functions as a contract manufacturer for branded med-tech companies while simultaneously developing and holding 510(k) clearances on its own-label products. This dual identity means it competes with Ethicon for hospital direct-supply business but also sells components to firms that in turn compete with Ethicon — a channel strategy that larger public incumbents cannot replicate without creating channel conflict. Ferguson and Coleman have maintained private ownership for two decades, with no disclosed succession plan or external capital events on the public record.